Patent drug costs come under scrutiny as China looks to improve HIV treatment
This article was originally published in Scrip
Spurred by the number of HIV carriers and AIDS patients in the country topping an estimated 780,000 by the end of 2011, China is to invest Yuan70 billion ($11 billion) by 2015 in the control of the disease, according to a new five-year plan released by the central government.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.